$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2023 Q3 Form 10-Q Financial Statement

#000141057823001831 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.710M $2.655M
YoY Change -11.58% 7.14%
% of Gross Profit
Research & Development $3.330M $2.794M
YoY Change -11.81% -45.35%
% of Gross Profit
Depreciation & Amortization $65.00K $67.00K
YoY Change -7.14% -5.63%
% of Gross Profit
Operating Expenses $3.330M $2.794M
YoY Change -11.81% -45.35%
Operating Profit -$6.035M -$5.449M
YoY Change -11.78% -28.22%
Interest Expense $4.930M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$120.0K $120.0K
YoY Change 605.88% -78.18%
Pretax Income -$1.230M -$5.329M
YoY Change -82.06% -24.31%
Income Tax
% Of Pretax Income
Net Earnings -$1.226M -$5.329M
YoY Change -82.12% -24.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.13
Diluted Earnings Per Share -$0.03 -$0.13
COMMON SHARES
Basic Shares Outstanding 45.02M 39.41M
Diluted Shares Outstanding 44.25M 39.70M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.420M $748.0K
YoY Change -80.79% -93.89%
Cash & Equivalents $1.222M $546.0K
Short-Term Investments $200.0K $202.0K
Other Short-Term Assets $60.00K $372.0K
YoY Change 17.65% -16.4%
Inventory
Prepaid Expenses
Receivables $70.00K $93.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.539M $1.213M
YoY Change -79.49% -90.53%
LONG-TERM ASSETS
Property, Plant & Equipment $752.0K $799.0K
YoY Change -25.02% -25.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.143M $4.534M
YoY Change -27.97% -26.34%
Total Long-Term Assets $4.143M $4.534M
YoY Change -27.97% -26.34%
TOTAL ASSETS
Total Short-Term Assets $1.539M $1.213M
Total Long-Term Assets $4.143M $4.534M
Total Assets $5.682M $5.747M
YoY Change -57.13% -69.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.926M $5.190M
YoY Change -38.61% -1.93%
Accrued Expenses $63.00K $90.00K
YoY Change 8.62% 104.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.321M $7.691M
YoY Change -29.36% -1.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.940M $1.938M
YoY Change -33.52% -40.63%
Total Long-Term Liabilities $1.943M $1.938M
YoY Change -33.41% -40.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.321M $7.691M
Total Long-Term Liabilities $1.943M $1.938M
Total Liabilities $8.264M $9.629M
YoY Change -30.36% -13.33%
SHAREHOLDERS EQUITY
Retained Earnings -$209.0M -$208.0M
YoY Change 8.29% 11.83%
Common Stock $207.0M $204.4M
YoY Change 6.52% 5.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.582M -$3.882M
YoY Change
Total Liabilities & Shareholders Equity $5.682M $5.747M
YoY Change -57.13% -69.69%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.226M -$5.329M
YoY Change -82.12% -24.31%
Depreciation, Depletion And Amortization $65.00K $67.00K
YoY Change -7.14% -5.63%
Cash From Operating Activities -$6.409M -$6.778M
YoY Change 32.14% 10.5%
INVESTING ACTIVITIES
Capital Expenditures $18.00K $0.00
YoY Change 1700.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $10.00K $4.000K
YoY Change -200.0% -42.86%
Cash From Investing Activities -$12.00K $4.000K
YoY Change 9.09% -133.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.097M 5.299M
YoY Change
NET CHANGE
Cash From Operating Activities -6.409M -6.778M
Cash From Investing Activities -12.00K 4.000K
Cash From Financing Activities 7.097M 5.299M
Net Change In Cash 676.0K -1.475M
YoY Change -113.91% -76.0%
FREE CASH FLOW
Cash From Operating Activities -$6.409M -$6.778M
Capital Expenditures $18.00K $0.00
Free Cash Flow -$6.427M -$6.778M
YoY Change 32.49% 10.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40926745
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36694078
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45015800
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
546000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
772000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
202000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
2211000
CY2023Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
93000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
91000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
372000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
1213000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3106000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
22000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
23000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3713000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4389000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
799000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
933000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4534000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5345000
CY2023Q2 us-gaap Assets
Assets
5747000
CY2022Q4 us-gaap Assets
Assets
8451000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5190000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6224000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
90000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
84000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1354000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1427000
CY2023Q2 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1057000
CY2022Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1065000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7691000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8800000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1938000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2666000
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1938000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2666000
CY2023Q2 us-gaap Liabilities
Liabilities
9629000
CY2022Q4 us-gaap Liabilities
Liabilities
11466000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40926745
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36694078
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
204431000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
194910000
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208209000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197821000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3882000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5747000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8451000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5718000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7729000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2794000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5113000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4882000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5337000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2655000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2478000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10600000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13066000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5449000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7591000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-212000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-665000
CY2023Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-120000
CY2022Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
550000
us-gaap Net Income Loss
NetIncomeLoss
-10388000
us-gaap Net Income Loss
NetIncomeLoss
-12401000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5329000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38224230
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38224230
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36461667
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36461667
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39696665
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39696665
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36486180
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36486180
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
505000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14487000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
405000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7851000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000
CY2023Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
3230000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4840000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
988000
CY2023Q2 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
5299000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5329000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3882000
us-gaap Profit Loss
ProfitLoss
-10388000
us-gaap Profit Loss
ProfitLoss
-12401000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-5329000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-7041000
us-gaap Depreciation
Depreciation
134000
us-gaap Depreciation
Depreciation
145000
CY2023Q2 us-gaap Depreciation
Depreciation
67000
CY2022Q2 us-gaap Depreciation
Depreciation
71000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
992000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
910000
CY2023Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
988000
CY2022Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
405000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-125000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-612000
CY2023Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-46000
CY2022Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-495000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
341000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-624000
CY2023Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-238000
CY2022Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-301000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1034000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1592000
CY2023Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2612000
CY2022Q2 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
722000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-80000
CY2023Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-84000
CY2022Q2 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-97000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10764000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9822000
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6778000
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6134000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
CY2022Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2009000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
1000
CY2023Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-4000
CY2022Q2 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2009000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4000
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
bcli Proceeds From At Market
ProceedsFromAtMarket
8529000
CY2023Q2 bcli Proceeds From At Market
ProceedsFromAtMarket
5299000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8529000
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5299000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-226000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9851000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1475000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6146000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2021000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15151000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
546000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9005000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
546000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9005000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208000000
us-gaap Operating Lease Payments
OperatingLeasePayments
1290000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2023Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
290000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3713000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3292000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M9D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0675
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
695000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1385000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1285000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
185000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3550000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
258000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3292000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
159000000
us-gaap Share Based Compensation
ShareBasedCompensation
992000
us-gaap Share Based Compensation
ShareBasedCompensation
910000

Files In Submission

Name View Source Status
0001410578-23-001831-index-headers.html Edgar Link pending
0001410578-23-001831-index.html Edgar Link pending
0001410578-23-001831.txt Edgar Link pending
0001410578-23-001831-xbrl.zip Edgar Link pending
bcli-20230630.xsd Edgar Link pending
bcli-20230630x10q.htm Edgar Link pending
bcli-20230630xex31d1.htm Edgar Link pending
bcli-20230630xex31d2.htm Edgar Link pending
bcli-20230630xex31d3.htm Edgar Link pending
bcli-20230630xex32d1.htm Edgar Link pending
bcli-20230630xex32d2.htm Edgar Link pending
bcli-20230630xex32d3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
bcli-20230630_pre.xml Edgar Link unprocessable
bcli-20230630_lab.xml Edgar Link unprocessable
bcli-20230630_def.xml Edgar Link unprocessable
bcli-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20230630x10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending